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Summary
Peritumoral injection of recombinant human interleukin 1 (3 (IL1(3) in mice transplanted
subcutaneously with Friend erythroleukemia cells (FLC) resulted in a marked increase in survival
time and inhibition of metastatic tumor growth in liver and spleen . In contrast, IL-2 treatment
alone did not significantly inhibit the development ofFLC metastases . A synergistic antitumor
effect was observed after combined IL-1/11r2 therapy of these mice. The antitumor action of
IL1/IL2 treatment was abolished or markedly reduced in mice treated with antibodies to CD4
or CD8 antigens, whereas antibodies to asialo-GM, were ineffective . A clear-cut increase in the
percentage ofCD4+ cells was observed in the spleens of cytokine-treated mice on days 17 and
23 . On day 23 of rytokine therapy, CD8+ cells were increased in both spleens andlymph nodes .
On day 17, infiltrates of host-reactive cells (i .e ., lymphocytes, granulocytes, and monocytes) were
observed in both spleen and liver from FLC-injected mice treated with IL-1/IL-2, in association
with tumor cells. On days 17 and 23, spleen cells and cells recovered from mesenteric lymph
nodes of IL1/IL2-treated mice exerted a potent antitumor effect as determined by Winn assay
experiments. This antitumor activity was abolished by preincubation of spleen cells with anti-
CD8 antibody, but not by treatment with antibodies to asialo-GMI ; antibodies to CD4 exerted
only a slight effect . Combined IL1/IL2 therapy was more effective on established (i .e ., 6-7-d)
FLC tumors than on early (i.e., 1-d) tumor-transplanted mice . IIr1/IL2 treatments were also
highly effective in increasing survival time ofmice fromwhich the subcutaneous primary tumors
were excised 7 d after FLC injection . These data indicate that in mice injected with FLC, the
antitumor effects of IL-1/IL-2 are mediated by CD4+ and CD8+ cells (but notNK cells), and
suggest that this combined cytokine treatmentmay be effective against established metastatic tumors.
R ecent data indicate that the combined treatment oftumor-
bearing animals with multiple cytokines results in a
more potent antitumor effect than single cytokine therapy
(1-7), thus suggesting that combined cytokine therapy rep-
resents an interesting approach to the treatment ofsomehuman
cancers. In the present study, we have investigated the effects
and antitumor mechanisms ofcombined treatment with ILA
and IL2 in mice transplanted with highly malignant Friend
erythroleukemia cells (FLC), 1 which metastasize to the liver
and the spleen (8) .
'Abbreviations used in this paper . FLC, Friend erythroleukemia cells ; LAK,
lymphokine-activated killer.
IL1, a cytokine mainly produced by stimulated mono-
cytes/macrophages, promotesT and B lymphocyte activation
and induces a wide range of biological effects in vitro and
in vivo (9-11) . However, little data are available on the an-
titumor effects of IIA in experimental tumors (12-17) . In
contrast, a number of studies have reported that IIA exerts
marked antitumor effects in both experimental animals and
cancer patients (18-20) . It has been suggested that the an-
titumor effects of IIA are mediated by the in vivo generation
of lymphokine-activated killer (LAK) cells (21, 22), although
a direct correlation has not been shown between the in vivo
antitumor efficacy of IIA and the in vitro cytolytic activity
of LAK cells against a variety of mouse tumors (17, 23) .
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metastatic FLC to investigate the antitumor effects of IFN-
ca/(3 (24-28), TNT-tx (29, 30), ILA (16, 17), and 11,2 (17) .
Peritumoral injections of IL-2, alone or in combinationwith
LAK cells, did not inhibit the development ofspleen or liver
metastases, although some inhibition of theprimary subcu-
taneous FLC tumorwas observed (17) . In contrast, injection
of 11,10 resulted in a marked reduction of tumor growth
and in an increased survival time, as compared with control
mice (16, 17). In preliminary experiments, we observed that
the combined treatment with 1171 and IL2 of mice trans-
plantedwith FLCresulted in an antitumor effect greater than
that observed with either cytokine alone (17) . In the present
study, we have described the synergistic antitumor effects of
thecombined IL1/IL2 treatment in mice injected with FLC
and we have characterized the host mechanisms involved in
this antitumor response. Furthermore, we provide evidence
that this combined cytokine treatment is markedly effective
in inducing the regression of established liver and spleen
metastases .
Materials and Methods
Mice. 6-8-wk-old male DBA/2 mice were obtained from
CharlesRiver BreedingLaboratories (Italia Calco, Italy) .Nude mice
were kept under specific germ-free conditions using sterile filters .
Tumor Cells. IFN-tx//3-sensitive 745 and IFN-a/a-resistant
3C1-8PLC (31) were serially passaged intraperitoneally in syngeneic
DBA/2 mice (in vivo passaged FLC) . These FLC are highly
metastatic to the spleen and to the liver (8) and exhibited a specific
membrane glycoprotein pattern as compared with that of thenon-
metastatic in vitro passaged FLC (32) .
11,2,11-1/3, and Control Preparations .
￿
Human rIIL2 (sp act, 3 x
106 U/mg of protein) (Hoffmann-La Roche, Inc ., Nutley, NJ) was
obtained through the National Cancer Institute (Dr . MichaelJ .
Hawkins, Chief of the InvestigationalDrug Branch). Electropho-
reticallypure human rI1,10 (mature fragment 117-269, expressed
in Escherichia coli) had a specific activity ofN5 x 108 half-maximal
U/mg of protein in the D10.G4.1 proliferation assay (33) . IL10
was provided by Sclavo (Siena and Cassina de Pecchi, Italy), through
the courtesy of Dr. D . Boraschi (Centro Ricerche Sclavo, Siena) .
Cytokines were diluted in physiologic solution (153mM NaCl);
endotoxin contamination was<0 .1 ng/mg as determined by limulus
amoebocyte lysate assay. Control preparations consisted of physio-
logic solution unless otherwise stated.
Antibodies to Asialo-GM,, CD4, and CD8 . Anti-asialo-GM,
rabbit antibody (10 mg/ml) (34, 35) was purchased from Wako
Chemicals (Neuss 1, FRG) . DBA/2 spleen cells taken from mice
injected three times intravenously with 50,ug of antibody to asialo-
GM, (days 0, +7, +11) showed no significant NK cell cytotox-
icity for mouse YAC cells in vitro .
The rat hybridoma cell mAb GK1-5 (36, 37) producing mAb
toCD4(L3T4) was provided by Prof . G . Forni (Institute ofMicrobi-
ology, University of Turin, Turin, Italy) . Hybridoma cells were
passaged intraperitoneally in BALB/c nude mice in our laboratory.
The Ig fraction of ascitic fluids was separated by ammonium sul-
fate precipitation . The protein concentrationwas N10 mg/ml . In-
travenous injection ofDBA/2 mice with 500 NAg of the anti-CD4
Ig resulted in complete depletion ofCD4* spleen cells, 6-9 d after
inoculation ofantibody, as determined by flow cytometric analysis
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using a FITC-labeled anti-CD4 mAb (Becton Dickinson & Co .,
Mountain View, CA).
TheIg fraction of ascitic fluids from the rat hybridoma cellmAb
53-6.7 (38) producing mAb to CD8 (Lyt-2) was separatedby am-
monium sulfate precipitation .
Intraperitoneal injection ofDBA/2 micewith 1 mg ofanti-CD8
Ig resulted in complete depletion of CD8' spleen and lymph
nodes cells when tested 15dthereafter by flow cytometric analysis
using a FITC-labeled anti-CD8 mAb.
Silica . Silica particles (average size <5 um) were provided
through the generosity of Dr. K. R6bock (Steinkohlenbergbau-
verein, Essen-Krey, FRG) . Mice were injected intravenously with
5 mg of silica particles. This dose hadbeen shown to be effective
in destroying peritoneal macrophages after intraperitoneal injection .
Flow CytometricAnalysis ofHostCellsfrom FLC-injectedMice.
￿
The
phenotypes oflymphoid cells present in lymph nodes and spleens
o£ animals injected with FLC were evaluated by direct immuno-
fluorescence using specific mAbs .
Spleen and mesenteric lymph nodes were removed aseptically
and washed with the hub of a syringe in RPMI 1640 . The cell
suspension and spleen or lymph node fragments were then passed
through a single layer of 100-gauge nylon mesh,and the cells were
centrifuged on a Ficoll-Hypaque gradient . After three washes in
RPMI 1640, light density cells were resuspended in RPMI 1640
and aliquots of 106 cells were incubated for 60 min at 4°C in the
presence of a 1:20 dilution of oneofthe following mAbs conjugated
with either FITC or PE (Becton Dickinson & Co.) : control rat
IgG1 or IgG2 ; anti-Lyt-2 (anti-CD8) ; anti-L3T4 (anti-CD4) ; anti-
Thy-1.2 . After three washes in cold Hank's saline solution, the
cells were resuspended in Hank's formalin and analyzed with aFAC-
Scan (Becton Dickinson & Co.) .
Winn Assay.
￿
Peritoneal cells and cells recovered from the spleens
or mesenteric lymphnodes were washed with saline, counted, and
mixed with 5 x 10° in vivo passaged 3C1-8 FLC (E/T cell ratios
were 20:1) . Cells were subsequently injected subcutaneously in 6-8-
wk-oldDBA/2mice . Thepercentage ofmice that developed sub-
cutaneous tumors wasdetermined 30-90d after the subcutaneous
injection .
Statistical Analyses.
￿
Data were analyzed by student's t test .
Light Microscopy Studies.
￿
Mice were killedby ether. Primary sub-
cutaneous tumors, spleens, and livers were removed, cut into two
pieces of -0.5 cm 3 , and fixed in 10% formalin for several days .
Fixed tissues were subsequently processed for paraffin embedding,
cut into 2-3-pm-thick slices, and stained with hematoxylin and
eosin.
Results
SynergisticAntitumorE$ectofCombined 11,1 and 11,2 Treat-
ment. Table 1 summarizes the results of five experiments
in which DBA/2 mice were injected subcutaneously with
different FLC types andsubsequently treatedwith 11,2, IL1,
or a combination of both cytokines. In all cases, combined
ILl/IL2 treatment resulted in an antitumor effect greater
than that observed with either cytokine alone, even though
some variability of the antitumor activity was observed .
Fig . 1 (A) shows a representative experiment on the syn-
ergistic antitumor effect of combined IL1/IL2 treatment.
Thus, DBA/2 mice were injected subcutaneously with highly
metastatic 3C1-8 FLC and, after 1 d, the mice were treated6-8-wk-old male DBA/2 mice were injected with different FLC types. 24 h after tumor injection, mice were treated peritumorally (0.2 ml per
mouse, twice a day: approximately 10 am and 6 pm) on days 2, 3, 4, 7, 8, 9, 14, 15, 16, 20, 21, and 22. IL-1 and IL-2 were injected together
in a total 0.2 ml volume . IL-1, 250 ng/treatment ; IL-2, 20,000 U/treatment. Survived mice were killed 100-135 d after FLC injection and were
found to be tumor free .
subcutaneously (i.e., peritumorally) with IL10, IL-2, or a com-
bination of both cytokines . Subcutaneous injection of IL1f3
resulted in marked inhibition of tumor growth (data not
shown) and a clear-cut increase in survival time, as compared
with control FLC-injected mice (Fig. 1A) . In agreement with
previous findings (17), subcutaneous treatment with 11,2 alone
resulted in some inhibition oftumor growth, but only a slight
increase in survival time as compared with control mice was
observed . As shown in Fig . 1 (A), the concomitant treat-
ment with both ILA and 11,2 resulted in a synergistic an-
titumor effect . On days 8-10, all treated mice in this group
developed smallFLC tumors, comparable with those of con-
trol mice . On day 10, the mean surface area of these tumors
was 60.8 ± 5.0 . These IL1/IL2-treated tumors regressed
3-4 wk after tumor cell injection and a few days after treat-
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ment had been discontinued. All control and IL-2-treated mice
died with extensive liver and spleen metastases. In contrast,
30% of the I14-treated mice were tumor free 140 d after
tumor cell injection . The combined IM/IL-2 treatment
resulted in complete regression of the tumor and recovery
in 60% of the FLC-injected mice . At death, the IIL1/IIL2-
treated mice injected with the in vivo passagedFLC exhibited
liver and spleen metastases, indicating that this combined
cytokine treatment did not modify the in vivo behavior of
FLC . As shown in Fig. 1(B), combined 11,1/IL2 peritumoral
treatment resulted in a slight decrease in body weight as com-
pared with control animals, within 1-2 wk of cytokine ad-
ministration . However, no toxicity was observed at any time
during ILlAL2 treatment .
In vitro treatment of FLC with IL-1 (50 ng/ml), IL-2
Table
Exp .
1 . Synergistic Antitumor
FLC type
Effects of Combined
No . of FLC
injected
IL-1/IL-2 Treatment in
No .
Treatment
Mice Injected Subcutaneously
of mice dead at day 60/
total No . of mice
with Diffferent FLC Types
No . of tumor-free mice/
total No . of mice
1 in vivo passaged 5 x 106 Saline 6/6 0/6
745 IL-2 6/6 0/6
IL-1 4/6 1/6
IL-1/IL-2 1/6 3/6
2 in vivo passaged 2 x 106 Saline 10/10 0/10
745 IL-2 9/9 0/9
IL-1 8/10 0/10
IL-1/IL-2 3/10 2/10
3 in vitro passaged 5 x 106 Saline 6/6 0/6
3C1-8 IL-2 5/6 0/6
IL-1 4/6 1/6
IL-1/IL-2 1/6 3/6
4 in vivo passaged 2 x 10 6 Saline 10/10 0/10
3C1-8 IL-2 9/9 0/9
IL-1 6/9 1/9
IL-1/IL-2 1/9 4/9
5 in vivo passaged 2 x 106 Saline 10/10 0/10
3C1-8 IL-2 10/10 0/10
IL-1 5/10 3/10
IL-1/IL-2 2/10 6/10
Total values Saline 42/42 0/42
IL-2 39/40 0/40
IL-1 27/41 6/41
IL-1/IL-2 8/41 18/41(2,000-20,000 U/ml), or a combination of both cytokines
did not result in significant inhibition of cell proliferation
1-3 d after cell seeding (data not shown) .
Efficacy o,f11,1/11,2 Treatment in Mice InjectedSubcutaneously
withFLC and Treated with Antibodies to CD4, CD8, or Asialo-
GMi . It was of interest to determine the antitumor effects
of Ilr1/IL2 treatment in mice whose immune response was
defective because of the injection ofantibodies directed against
specific cell types. As shown in Table 2, the antitumor effect
of Ilr1/IL2 therapy was completely abrogated in mice treated
with anti-CD4 antibody. Injection of anti-CD8 antibody also
resulted in a marked reduction of the IL1AL2 antitumor
effects. In contrast, treatment with anti-asialo-GM, anti-
body, which completely inhibited specific NK cell activity,
did not significantly affect the antitumor activity of IL1/
IL2 (Table 2) . Injection of mice with silica, which has been
shown to be toxic for macrophages, partially inhibited the
antitumor effects of the IL1/IL2 treatment (data not shown) .
Effects of 11,1/11,2 Treatment on Lymphocyte Subsets in the
Spleen andLymph Nodes ofFLC-injectedDRA/2 Mice . IL1/
IL2 treatment of mice injected subcutaneously with FLC
resulted in a marked increase in the percentage of CD4+
spleen cells on days 17 and 23 after tumor cell injection (i .e .,
a twofold and a fivefold increase, respectively) . On these days,
a slight increase in the percentage of CD4+ cells was also
observed in the mesentericlymph nodes of Ilr1/IL2-treated
mice (data not shown) . Moreover, the flow cytometric anal-
yses of host cells recovered on day 23 from FLC-injected mice
revealed a clear-cut increase in the percentage ofCD8+ cells
in the spleens and lymph nodes of IIr1/IL2-treated mice (i .e.,
a 12-fold and a twofold increase, respectively) (data not shown) .
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Antitumor effects of peritumoral injection of ILl,Q, alone
or in combination with 11,2, in mice transplanted subcutaneously with
3C1-8 FLC . 7-wk-old male DBA/2were injected subcutaneously with 2
x 106 in vivo passaged 3C1-8 FLC . On day 1, mice were divided into
the following groups : (a) saline; (b) IL1s; (c) 11,2 ; (d) 11,10 + IL2 . Treat-
ments were performed as described in detail in the footnote to Table 1 .
There were 10 mice in each experimental group. On day 140, surviving
mice were killed and found to be tumor free. (A) The percent of surviving
mice at different days after tumor cell injection . (E) Saline-treated mice;
(A) I1,2-treated mice; (") ILl-treated mice; (n)IL1/IL2-treated mice .
(B) The mean body weight of mice treated with saline (E) or IL-1 +
IL-2 (0) . The SEs are within the symbols.
Generation of Effector Cells Endowed with Potent Antitumor
Activity during H,1/1L2 Treatment ofFLC-injected Mice . The
livers and spleens of FLC-injected mice were examined by
light microscopy at different times after Ilr1/IL2 treatments .
On days 10, 14, 17, and 20, the histologic examination of
livers and spleens of FLC-injected mice revealed the presence
of both tumor cells and infiltrating host cells . Apparent
micrometastases were observed in the livers of ILlAL2-treated
Table 2 .
￿
Effects of Injection of Antibodies to Specific Cell Types on the Antitumor Activity of IL-11IL-2 Treatment
6-8-wk-old male DBA/2 mice were injected subcutaneously with 5 x 106 3C1-8 FLC. Some mice were treated with different antibodies as described
in Materials and Methods . 1 d after FLC injection, mice were treated subcutanteously with saline or IL-1+ IL-2 as described in the legend to
Fig. 1, on days 1, 2, 3, 7, 8, 9, 13, 14, and 15 . Surviving mice were killed 120 d after tumor injection and found to be tumor free .
'p < 0.001 .
Exp . Treatment Antibody Mean day of death
± SE
Tumor-free
mice
1 Saline - 34 ± 3.2 0/8
Saline Anti-CD4 27 ± 3.0 ~NSJ* 0/8
IL-1/3 + IL-2 - 57 ± 10.4 * 2/7
IL-10 + IL-2 Anti-CD4 25 ± 1 .1 0/8
2 Saline - 28 ± 1 .1 0/8
Saline Anti-CD8 27 ± 1 .4
INSi*
0/10
IL-1 + IL-2 - 48 ± 2.6
1.
1/5
IL-1 + IL-2 Anti-CD8 29 ± 6 .5 1/5
3 Saline - 25 ± 1 .7
INS
0/8
Saline Anti-asialo-GM, 25 ± 3 .1 0/8
IL-1/3 + IL-2 - 65 ± 11.4~ ]~ 1/7
IL-1/3 + IL-2 Anti-asialo-GM, 51 ± 4 .4 -'NS 0/8Figure 2 .
￿
Histologic changes in the liver and primary subcutaneous tumor of 11,1/11,2-treated mice injected with FLC. (A) Liver of a saline-treated
mouse on day 17 after FLC injection. A typical FLC metastasis is observed without evidence of host cell infiltrates ( x130). (B) Liver of a mouse treated
with II1,1/II1,2 (day 17) . Large areas of tumor cells are observed together with the appearance of host cell infiltrates (x130) . (C) Same liver, as in B,
at a higher magnification (x670) . Infiltrating lymphocytes (ly) and granulocytes (gr) as well as tumor cells (tc) are observed. (D) Primary subcutaneous
tumor from a saline-treated mouse (day 17) (x330) . (E) Primary subcutaneous tumor from a mouse treated with I1T1/I1,2 (day 17) . Note the hemor-
rhagic tumor necrosis, host cell infiltrates, and degenerating tumorcells (x130) . (F) Same tumor, as in E, at higher magnification (x840) . Lymphocytes,
granulocytes (gr), and monocytes are occasionally observed .
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covered from the spleens of IL-1/11,2-treated FLC-injected
mice were seeded in medium containing agarose to deter-
mine the number of FLC colonies (24) .
Values ranging from 1.2 x 104 to 2.5 x 10 5 FLC per
spleen were found by counting the FLC colonies grown in
agarose, indicating that a consistent number of tumor cells
were present in the spleens ofILl/IL2-treatedmice. On day
17, infiltrates of host-reactive cells (i .e ., lymphocytes, granu-
locytes, and monocytes) were clearly observed in both spleen
(data not shown) and liver (Fig . 2,BandC) from FLC-injected
mice treated with lLl/IL2 . At this time, large areasof hemor-
rhagic tumor necrosis were present within the primary sub-
cutaneous tumors from the treated mice (Fig. 2E), and similar
host cell infitrates were detected (Fig . 2 F) .
Experiments were then performed to determine whether
host cells from cytokine-treated mice might exert some an-
titumor activity in typical Winn assays . No antitumor ac-
tivity was found using spleen cells, peritoneal cells, or cells
from lymph nodes of mice on day 10 of cytokine therapy
(data not shown) . In contrast, aclear-cut antitumor activity
was exhibited by host cells recovered from the spleens and
lymph nodes of mice on days 17 and 23 of treatment with
IL1/IL2 (Table 3) . This antitumor activity was abolished
by pretreatment of spleen cellswith anti-CD8 antibody, but
not by preincubation with anti-asialo-GM i antibodies (Fig.
3) . A slight inhibition of tumor growth was observed by
treatment of spleen cells with antibodies to CD4 (Fig. 3) .
ILI/IL2 Treatment Is More Effective in Mice with Established
FLC Tumors Than in Early Transplanted Mice. The data pre-
sented above suggestedthat IL1AL2 treatment was effective
Table 3.
￿
Antitumor Activity ofHost Cells Recoveredfrom
Cytokine-treated FLC-injected Mice (Winn test)
7-wk-old male DBA/2 mice were injected subcutaneously with 2 x 106
in vivo passaged 3C1-8FLC . Treatment was as follows : 0.2 ml of either
saline or IL-la+ IL-2 (250 ng and 20,000 U, respectively) injected twice
(i .e ., at approximately 10 am and 6 pm) on days 1, 2, 3, 7, 8, 9, 14,
15, and 16 . On day 17 of tumor growth, pooled cells recovered from
each experimental group were mixed with 5 x 104 in vivo passaged
FLC and injected subcutaneously into DBA/2 mice . There were six mice
in each group .
' The E/T cell ratio was -20:1 .
t The E/T cell ratio was -10:1 .
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Characterization of cells endowed with antitumor activity
in spleens ofcytokine-treated mice. 7-wk-old male DBA/2 mice were in-
jected subcutaneously with 2 x 106 in vivo passaged 3C1-8 FLC . Treat-
ment was as follows : 0.2 ml ofeither saline or ILlO + 11,2 (250 ng and
20,000 U, respectively) injected twice a day (i .e., at approximately 10 am
and 6 pm) on days 1, 2, 3, 7, 8, 9, 14, 15, and 16 . Cells recovered from
the spleens of FLC-injected mice on days 17 and 23 were preincubated
for 30 min at 37°C with a suitable dilution of different antibodies . Cells
were then mixed with 5 x 104 3C1-8 FLC and subsequently injected sub-
cutaneously in 6-wk-old maleDBA/2 mice. TheE/T cell ratio was-20:1 .
There were eight mice per each group. The values represent the percentage
of protection by: 100x (No . ofmice without tumor) (Total No. of mice) .
All the miceinjectedonlywith FLC developed subcutaneous tumorswithin
15 d, similarly tomice injected subcutaneously with tumor cells plus spleno-
cytes from saline-treated mice. The number of tumor-free mice in each
group was determined 30 d after FLC injection .
in curing some FLC-injected mice even though some tumor
cells were present in their spleens and livers. It was of in-
terest, therefore, to study the antitumor effects ofIL1/IL2
treatments in mice with established solid tumors, as com-
Pretreatment of
splenocytes :
U
Treatment of
donor mice :
Antitumor Effects of Interleukin 1 and 2
none
￿
none anti-COB anti-CD4 anti-aGM 1
saline
￿
IL-11IL-2
Figure 4.
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Efficacy of 11,1/11,2 treatment in mice with 1-d or 6-d estab-
lished FLC subcutaneous tumors . 6-wk-old male DBA/2 mice were in-
jected subcutaneously with 2 x 10 6 in vivo passaged 3C1-8 FLC. Mice
were treated with saline or ILA + IL-2 on day 1 or 6 after tumor cell
implantation . ILl/IL2 treatments were performed as described in the legend
to Fig. 3 . There were 10 mice in each group. 1-d tumors were treated
on days 1, 2, 3, 7, 8, 9, 13, 14, and 15. 6-d tumors were treated on days
6, 7, 8, 13, 14, 15, 20, 21, and 23 . (/) Saline-treated mice (1 d) ; (0)
IL1/IL2-treated mice (1 d) ; (A) Saline-treated mice (6 d) ; (A) 11,1/11,2-
treated mice (6 d) .
No . of tumor-free mice (day 90)/
total No . of injected
effector cells from :
mice with
Peritoneal
Treatment Day Spleen' Lymph nodes' cavityt
Saline 17 0/6 0/6 0/6
IL-1/3 + IL-2 17 6/6 2/6 0/6
Saline 23 0/6 0/6 ND
IL-1 + IL-2 23 3/6 6/6 NDpared with mice transplanted with FLC 1 d before the start
of cytokine treatment .
Fig. 4 shows a representative experiment in which the
efficacy of IL1AL2 treatment was compared in mice with
1- or 6-d implanted tumors. IL1/IL2 therapy appeared to
be more effective on established FLC tumors than on early
FLC-transplanted mice. Similar results were obtained com-
paring the efficacy ofILlAL2 treatments on 1- and 7-d FLC
tumors (data not shown) .
Fig . 5 shows the effect of the combined cytokine treat-
ment on the growth of established (i.e., 6-d) FLC tumors .
IL1AL2 treatment resulted in a complete arrest of tumor
growth . In this experiment, 30% of the 11,1/11L,2-treated
mice exhibited a complete tumor regression and were con-
sidered to be tumor free 120 d after FLC injection .
IL1/IL2 Treatment Is Elective as Adjuvant Therapy after Sur-
gery in the Inhibition ofLiver and Spleen Metastases. The ex-
periments described above were performed by treating FLC-
injected mice peritumorally . Therefore, it was not possible
to distinguish between the effects of cytokines on the pri-
mary subcutaneous tumor vs. the effects on metastases. On
the other hand, intraperitoneal or intravenous treatments with
IL-1/IL-2 of mice injected subcutaneously with FLC were less
effective in inhibiting tumor growth and exhibited some tox-
icity, which was not observed after subcutaneous cytokine
treatments (data not shown) .
It was ofinterest, therefore, to study the antitumor effect
of the subcutaneous I171/IL-2 treatment after surgical abla-
tion of the subcutaneous primary tumor. Thus, we excised
the established subcutaneous tumors on day 7, when tumor
cells had metastasized to the spleen and to the liver of most
h
E
E
400-
Figure 5 .
￿
Effect of IL1AL2 treatment on the growth of established
FLC subcutaneous tumors. 6-wk-old male DBA/2 mice were injected sub-
cutaneously with 2 x 106 in vivo passaged 3C1-8 FLC. Mice were treated
with saline or IIA + 11,2 on day 6 after tumor cell injection . 11,1/IL2
treatments were performed as described in the legend to Fig . 3, on days
6, 7, 8, 13, 14, 15, 20, 21, and 23 . There were 10 mice in each group.
3 of 10 ILlAL2 treated mice exhibited a complete tumor regression 40-
52 d after FLC injection and were considered to be tumor free on day
120 . The arrow indicates the initiation oftumor therapy. (" ) Saline-treated
mice ; (O) 11,1/11,2-treated mice .
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Figure 6 .
￿
Effect of IIA/IL2 treatment as adjuvant therapy after sur-
gery of subcutaneous primary FLC tumors . 6-wk-old male DBA/2 mice
were injected subcutaneously with 5 x 106 3C1-8 FLC in the dorsal flank
region . After 7 d, some mice were anesthetized by ether, the tumor nodule
and immediate surrounding tissue were excised, and the skin edges were
tied with sutures ; the remaining mice were left with theprimary subcuta-
neous tumors. On day 9 of tumor growth, untreated mice (A) and surgi-
cally treated mice (B) were randomized and treated with 11,1/IL2 (0)
or saline (/) . Subcutaneous treatments were performed as described in
the legend to Fig. 3, on days 9, 10, 11, 16, 17, 18, 22, 23, and 24 . There
were 10 mice in each experimental group .
of the injected mice (data not shown) . On day 9, we treated
the mice subcutaneously with ILl/IL2 or a control prepara,
tion . As shown in Fig. 6, the combination of tumor resec-
tion and IL1/IL2 therapy resulted in a higher rate of sur-
vival as compared with control mice .
The present results indicate that combined IL1AL2 treat-
ment of mice injected subcutaneously with FLC results in
a synergistic host-dependent antitumor effect as compared
with single cytokine treatment (Table 1 and Fig. 1) . Syner-
gistic antitumor effects have also been described in a variety
of experimental tumors treated with different cytokines (1-7) .
In the IM/IL-2 treatment of FLC tumors, it is reasonable
to assume that most ofthe antitumor effect observed is caused
by IL10, as IL-2 alone does not significantly increase the sur-
vival time of FLC-injected mice . Little information is avail-
able on the antitumor effects of IM in mice (11-17), and
to the best of our knowledge, no data have been published
on the antitumor effects of ILA in mice transplanted with
highly metastatic tumor cells . We have observed that small
tumors initially developed in IA-treated mice and subsequently
regressed between the second and third week of treatment .This tumor regression was more rapid in mice treated with
both IL1 and IIr2, resulting in the cure of10-60% oftumor-
bearing mice . The fact that IIAO alone or in association with
Ilr2 did not exhibit a significant inhibitory effect on the in
vitro multiplication ofFLC suggests that the IWAL2-in-
duced antitumor effect was likely to be host mediated and
not related to direct cytostatic or cytotoxic effects of these
cytokines on the tumor cell themselves . In particular, the
finding that the 11,1/11,2 antitumor effect was completely
abrogated or markedly reduced in mice injected with anti-
bodies to CD4 and CD8 (Table 2) suggests that T cells, par-
ticularly T helper and cytotoxic lymphocytes, are involved
in the generation of this antitumor response. In contrast, NK
cells do not appear to play a relevant role in the antitumor
effects of IL1/IIr2, as the injection of antibody to asialo-
GMt did not significantly affect the antitumor effect of the
combined cytokine treatment (Table 2) .
It is emphasized that, althoughtumor cells were detected
by morphologic and biologic assays in the organs of cytokine-
treated mice, some of these mice were cured after IL1/IL2
therapy, thus suggesting the involvement of potent immune
mechanisms. In this regard, the following observations are
of interest : (a) an increased percentage ofCD4+ and CD8+
cells was detected in the spleens of FLC-injected mice on days
17 and 23 ; (b) at this time, host cell infiltrates (mostly lym-
phocytes and granulocytes) were clearly detected in situ (i.e.,
primary subcutaneous tumor, liver, or spleen metastases), in
close association with tumor cells, in the spleen, liver (Fig.
2, B and C), and primary subcutaneous tumor (Fig . 2E and
F) ; (c) likewise, host cells recovered from the spleens and lymph
nodes of these mice exhibited marked antitumor activity as
determined by Winn test experiments (Table 3) ; and (d) the
antitumor activity of spleen cells was abolished by preincu-
bation with antibodies to CD8 (but not with antibodies to
CD4 or asialo-GM,) (Fig . 3) . The finding that the anti-CD4
mAb is highly effective in vivo in abolishing the antitumor
effect of the 11,1/11,2 therapy, but is not significantly effec-
tive in inhibiting the ability of spleen cells to function in
a Winn assay, might be due to the fact that CD4+ cells play
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a crucial role in the generation process of the antitumor im-
mune response, but they are not directly involved in the cyto-
toxic effector mechanism . The final effector cells responsible
for the tumor regression are likely to be CD8+ cytotoxic T
lymphocytes, as suggested by the results of the Winn assay
experiments (Fig. 3) .
The finding that the IL1/IIr2 treatment was more effec-
tive on established (6-8-d) than on early (1-d) implanted sub-
cutaneous tumors (Fig . 4) is consistent with the observation
that some tumor cells were present in the liver and spleen
of cytokine-treated mice, before the in situ generation of host
immune cells could occur. In fact, at 6-8 d after subcuta-
neous FLC injection, when 11,1/IL2 therapy was started, FLC
micrometastases were already detectable in the spleen and liver
of the majority of these mice (data not shown) . In this re-
gard, North et al . (14) have recently reported that IL1/3 caused
regression of the immunogenic SA1 sarcoma, growing sub-
cutaneously in syngeneic mice, when given on days 6-8 of
tumor growth, but not when given on days 1-3 . It was thus
suggested that the antitumor action of ILA was based on an
underlying host-immune response that required some tumor
growth to be fully generated. Although the highly metastatic
in vivo passagedFLC appeared to benommmunogemc when
injected in DBA/2 mice (8, 17), the data presented in this
article on IWAI,2-treated mice seem to be in agreement with
those obtained by North et al . (14) in 11,1-treated mice. It
is possible to envisage that injection ofFLC primes the host's
immune system, which is then markedly amplified by IL
1/IL2 treatment .
The antitumor effect o£ 11,1/11,2 therapy was also observed
when the primary tumors were surgically removed (Fig . 6
B), demonstrating that this combined cytokine treatment can
exert antimetastatic effects, which are independent from the
effects on the primary tumor. It is reasonable to conclude
that knowledge of the host mechanisms operative in the po-
tent antimetastatic effect exerted by combined IIrl/11,2 treat-
ment of established FLC tumors may provide some insights
in defining new strategies for more effective combined cytokine
therapies in patients with advanced tumors.
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